Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 10/20 | 0.60 |
| ▸ | WIZ | O95785 | 3/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.55 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25087642 | 0.93 | IKZF2 (0.57) | IKZF2WIZCRBN | |
| SCHEMBL25087399 | 0.91 | IKZF2 (0.60) | IKZF2WIZCRBNTNF | |
| SCHEMBL25035421 | 0.90 | CRBN (0.61) | IKZF2WIZCRBNTNF | |
| SCHEMBL29311129 | 0.90 | CRBN (0.58) | IKZF2WIZCRBNTNF | |
| SCHEMBL25087643 | 0.89 | TNF (0.62) | IKZF2WIZCRBNTNF | |
| SCHEMBL29311025 | 0.89 | CRBN (0.60) | IKZF2WIZCRBNTNF | |
| SCHEMBL24079649 | 0.89 | WIZ (0.63) | IKZF2WIZCRBNTNF | |
| SCHEMBL22536267 | 0.88 | CRBN (0.58) | IKZF2WIZCRBNTNF | |
| SCHEMBL29310988 | 0.86 | CRBN (0.57) | IKZF2WIZCRBNTNF | |
| SCHEMBL29311461 | 0.86 | CRBN (0.56) | IKZF2WIZCRBNTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148088-A1 | SPIROCYCLOALKYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE IKZF2 | Plexium, Inc. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2021-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, HTR1D, RXFP1 | IKZF2 3604/4885WIZ 1518/4885CRBN 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.